Dr. Joris Heyligen, Reumatologie SRL
Dr. Joris Heyligen, Reumatologie reported total assets of 172,861 € at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Jun 2026).
The score of Dr. Joris Heyligen, Reumatologie shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +298 % Total assets +114 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dr. Joris Heyligen, Reumatologie's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jun 2026
- Year ended 31 Dec 2024filed on 22 Jul 2025
- Year ended 31 Dec 2023filed on 26 Apr 2024
Dr. Joris Heyligen, Reumatologie's financial analysis
- Solvency86.7%sector median: 72.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dr. Joris Heyligen, Reumatologie
1 active director(s) in the register.
Dr. Joris Heyligen, Reumatologie's shareholders and holdings →Dr. Joris Heyligen, Reumatologie's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0797.947.536
- VAT number
- No VAT activity declared to the CBE
- Peppol
- Registered · 0208:0797947536 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 02 Feb 2023
- Registered office
- 3740 Bilzen-Hoeselt
- Latest accounts
- 2025 · filed on 24 Jun 2026
- Activity
- Medical specialists activities (NACE 86220)
Dr. Joris Heyligen, Reumatologie (SRL) has been based in Bilzen-Hoeselt since 2023, active in: medical specialists activities. For 2025, it reports a net profit of 62,497 € and equity of 149,874 €; its revenue is not published. Its solvency stands at 86.7%, above the median of its sector (72.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Dr. Joris Heyligen, Reumatologie
Companies in the same business, of comparable size and area, outside its group.
- Couvreur - Zingueur Michiels Installation of industrial machinery and equipment Perwez · balance sheet 172,906 €
- Vinca General medical practice activities Genk · balance sheet 172,907 €
- Chamaeleo Pharma Manufacture of pharmaceutical preparations Merelbeke-Melle · balance sheet 172,711 €
- WMD Consulting Antwerp · balance sheet 172,910 €
- Marconiere Saint-Gilles · balance sheet 172,787 €
Frequently asked questions about Dr. Joris Heyligen, Reumatologie
What is the revenue of Dr. Joris Heyligen, Reumatologie?
Dr. Joris Heyligen, Reumatologie files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Dr. Joris Heyligen, Reumatologie?
According to the Crossroads Bank for Enterprises, no VAT-liable activity is declared for Dr. Joris Heyligen, Reumatologie. If it is VAT-registered, its VAT number is its company number prefixed with BE: BE0797947536. Its company number (CBE) is 0797.947.536.
Where is the registered office of Dr. Joris Heyligen, Reumatologie?
According to the CBE register, the registered office of Dr. Joris Heyligen, Reumatologie is in 3740 Bilzen-Hoeselt.
What is the equity of Dr. Joris Heyligen, Reumatologie?
At the close of the 2025 financial year, the equity of Dr. Joris Heyligen, Reumatologie amounts to 149,874 €, a solvency of 86.7% of total assets.
Who manages Dr. Joris Heyligen, Reumatologie?
The register lists 1 active mandates at Dr. Joris Heyligen, Reumatologie. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dr. Joris Heyligen, Reumatologie
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →